Neurologic Manifestations of the Arbovirus Infection in Colombia
NCT03206541 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 570
Last updated 2020-02-20
Summary
This is a multi-center case-control study that aims to define the association between the exposure to an arbovirus infection and the development of a neurological syndrome in patients from Colombia. The study makes part of the Neurovirus Emerging in the Americas Study (NEAS) that is a collaborative effort that looks to combine the efforts of researchers, healthcare providers and patients in Colombia to establish a comprehensive registry of the clinical, radiological and laboratory profile of patients with new onset of neurological diseases associated mosquito-borne viruses, known as arboviruses.
Conditions
- Encephalitis
- Myelitis
- Guillain-Barre Syndrome
- Cranial Nerve Palsies
- Meningitis
- Zika Virus Infection
- Dengue (Virus); Fever, Sandfly
- Chikungunya Fever
Sponsors & Collaborators
-
Universidad del Valle, Colombia
collaborator OTHER -
ZikaPLAN
collaborator UNKNOWN - lead OTHER
Principal Investigators
-
Carlos A Pardo-Villamizar, MD · Johns Hopkins University
-
Beatriz Parra, PhD · Universidad del Valle
-
Lyda Osorio, PhD · Universidad del Valle
Eligibility
- Min Age
- 8 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2016-01-01
- Primary Completion
- 2019-12-31
- Completion
- 2019-12-31
Countries
- Colombia
Study Locations
More Related Trials
-
LatInamerican Vaccine Effectiveness Against Hospitalizations Due to Circulating COVID-19 VoC RWE Study
NCT05282017 ·Status: COMPLETED
-
Chikungunya Virus Vaccine Trial in Healthy Adults
NCT01489358 ·Status: COMPLETED ·Phase: PHASE1
-
Assessment of Chikungunya Virus Seroprevalence Before VLA1553 Vaccination in the Municipalities Selected for Participation in the VLA1553 Pilot Vaccination Strategy in Brazil
NCT07163845 ·Status: ACTIVE_NOT_RECRUITING
-
Venezuelan Equine Encephalitis Monovalent Virus-Like Particle Vaccine
NCT03776994 ·Status: UNKNOWN ·Phase: PHASE1
-
Flavivirus Cross-priming Potential of IMOJEV
NCT03920111 ·Status: COMPLETED ·Phase: NA
-
Characterization of Human Memory Immune Responses to Prior Yellow Fever Vaccination
NCT01244802 ·Status: ENROLLING_BY_INVITATION
-
Digital Applications to Monitor Novel Coronavirus Disease and Response in Colombia - Syndromic and Vaccination Surveillance
NCT05764174 ·Status: COMPLETED ·Phase: NA
-
Study to Assess the Safety and Immunogenicity of a Chikungunya Virus Vaccine Candidate (VLA1553) in Healthy Volunteers
NCT03382964 ·Status: COMPLETED ·Phase: PHASE1
-
Safety Study of ChimeriVax™-JE Vaccine to Prevent Japanese Encephalitis.
NCT00314132 ·Status: COMPLETED ·Phase: PHASE3
-
Diagnostics and Surveillance of Acute Meningo-encephalitis Among Children in Cambodia With a Focus on Japanese Encephalitis Virus
NCT06674837 ·Status: NOT_YET_RECRUITING
-
A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants
NCT00474526 ·Status: COMPLETED ·Phase: PHASE3
-
A Trial to Evaluate the Safety and Immunogenicity of VLA1553 in Healthy Children
NCT07133178 ·Status: WITHDRAWN ·Phase: PHASE3
-
Safety and Efficacy Study of Intravenous Immunoglobulin to Treat Japanese Encephalitis
NCT01856205 ·Status: COMPLETED ·Phase: PHASE2
-
A Case-control Study of the Efficacy of a New Serogroup A Meningococcal Conjugate Vaccine (MenAfriVac) in Mali and Niger
NCT01303211 ·Status: WITHDRAWN
-
A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Ad26.ZIKV.001 in Healthy Adult Volunteers
NCT03356561 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase 2 Clinical Trial of VLA1553 in Healthy Children Aged 1 to 11 Years
NCT06106581 ·Status: COMPLETED ·Phase: PHASE2
-
A Safety and Efficacy Study of Two Japanese Encephalitis Vaccines ChimeriVaxTM-JE and JE-VAX
NCT00319592 ·Status: COMPLETED ·Phase: PHASE2
-
Safety Study of Meningococcal ACYW135 Polysaccharide Conjugate Vaccine in Healthy Volunteers Aged Above 3 Months
NCT02878291 ·Status: UNKNOWN ·Phase: PHASE1
-
Seamless Controlled Trial To Evaluate Safety And Immunogenicity of Chikungunya Vaccine in LatinAmerica and Asia
NCT04566484 ·Status: TERMINATED ·Phase: PHASE2/PHASE3
-
A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In US Adolescents and Adults
NCT00450437 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Immune Response of Novartis MenACWY-CRM Conjugate Vaccine When Given to Healthy Toddlers
NCT00626327 ·Status: COMPLETED ·Phase: PHASE3
-
A Multicenter Study to Evaluate Safety and Immunogenicity of a Live-attenuated Chikungunya Vaccine in Adolescents
NCT04650399 ·Status: COMPLETED ·Phase: PHASE3
-
Real-world Effectiveness, Safety and Immunogenicity of Chikungunya Vaccination in Populations at Risk of Severe or Complicated Forms: Prospective Study in La Réunion
NCT06928753 ·Status: RECRUITING ·Phase: PHASE4
-
Study of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America
NCT01374516 ·Status: COMPLETED ·Phase: PHASE3
-
Trial to Evaluate the Immunogenicity and Safety of the Co-administration of Live Attenuated Dengue and Chikungunya Vaccines Compared to Separate Administration in Adults Aged 18 to 59 Years.
NCT06973772 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3